摘要:

For antitumor drug sensitivity testing we have been performing the succinic dehydrogenase inhibition test using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-nyltetrazolium bromide (MTT). A new tetrazolium salt 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenyl-amino) carbonyl]-2H-tetrazolium hydroxide (XTT) has been synthesized recently, and we have been conducting basic studies using it. We were able to obtain a high degree of sensitivity by adding phenazine methosulfate as a promoter in this assay. In these assays, there was a positive correlation between absorbance and cell count and XTT assay was more sensitive than MTT assay. In XTT assay, the production of formazan increases with reaction time over a protracted period of time, we assessed the possibility of performing assays with fewer cells than MTT was used. The results using cancer cell lines showed that when reacted for a longer time (6 h), it was possible to perform adequate assays using this method with 5,000 cells per well, and it will be useful when the amount of biopsy specimen is limited. We also evaluated the inhibition index of each of the drugs, comparing it with the MTT assay.

ISSN:0030-2414    

DOI:10.1159/000227399

出版商:S. Karger AG    

年代:1994

数据来源: Karger

摘要:

The activities of established and experimental antitumor drugs were tested against the BRO and MeWo human melanomas transplanted in the subrenal capsule of phenotypically immunocompetent (CBA × C57BL/6)Fi mice. Immunosuppression was achieved with preliminary whole-body radiation, and cytological examination showed that the tumors of untreated mice consisted largely of viable tumor cells. Several drugs tested showed moderate activity against one or both tumors. The system described provides a basis for testing anticancer agents against a panel of human melanomas implanted in immunocompetent mice

ISSN:0030-2414    

DOI:10.1159/000227400

出版商:S. Karger AG    

年代:1994

数据来源: Karger

摘要:

Several analyses of the retinoblastoma (RB) gene in lung cancer at the DNA, mRNA and protein levels have recently been reported. In particular, small cell lung carcinoma shows a high incidence of RB gene abnormalities, suggesting that alterations of this gene may participate in tumor development. In the present study, we used an immunohistochemical technique with a monoclonal antibody raised against RB protein (PMG3-245) to detect its expression in representative paraffin sections of tissues obtained from 108 patients with various types of lung cancer treated by surgical resection of the primary tumor. While deletion of RB protein expression was observed in 7 (88%) of 8 small cell lung carcinomas, only 17 (17%) of 100 non-small cell lung carcinomas showed decreased RB protein levels and 6 (6%) showed no RB protein expression. This low incidence of RB protein expression abnormalities in non-small cell lung carcinomas was significant (p < 0.0001). Thus, in contrast to small cell lung carcinoma, abnormalities in RB protein expression may be minor events in non-small cell lung carcinoma. In addition, no significant correlation was found between abnormalities in RB protein expression and clinical factors such as stage, tumor size, and nodal involvement in non-small cell lung carcinoma. However, abnormalities in RB protein expression in squamous cell carcinoma were observed only in the less differentiated types (p = 0.144), and there was a weak but not statistically significant association in non-small cell lung carcinoma between RB protein status and prognosis (p = 0.09). Therefore, in non-small cell lung carcinoma, although abnormalities in RB protein appear not to be closely associated with tumor development, further studies on a larger scale and with a longer-term follow-up are required to determine the clinicopathological significance of RB gene abnormalities, in particular the relationship between abnormalities of RB protein and differentiation or prognosis.

ISSN:0030-2414    

DOI:10.1159/000227401

出版商:S. Karger AG    

年代:1994

数据来源: Karger

摘要:

In this study the dose-response curves for doxorubicin, pirarubicin, 5-fluoro-uracil, 4-hydroperoxy-cyclophosphamide and taxol were obtained in three breast cancer cell lines (MCF-7, T47D and BT-20). The ATP cell viability assay was chosen to evaluate the chemosensitivity profiles and was a reproducible, practicable method to assess drug response in breast cancer cell lines. The IC50 values were calculated on the median effect principle and indicated that taxol was the most active drug tested in this study with a mean IC50 value of 0.02 μM. This in vitro effect correlated well with clinical observations in metastatic breast cancer where taxol proved to be a very active drug. Pirarubicin was the second most active drug tested with an IC50 value 10 times less compared to that of doxorubicin. The results obtained with the ATP cell viability assay are promising, therefore further testing with drug combination chemotherapy and fresh human breast cancer tumor testing are warranted and ongoing

ISSN:0030-2414    

DOI:10.1159/000227402

出版商:S. Karger AG    

年代:1994

数据来源: Karger

ISSN:0030-2414    

DOI:10.1159/000227403

出版商:S. Karger AG    

年代:1994

数据来源: Karger

ISSN:0030-2414    

DOI:10.1159/000227404

出版商:S. Karger AG    

年代:1994

数据来源: Karger

ISSN:0030-2414    

DOI:10.1159/000227405

出版商:S. Karger AG    

年代:1994

数据来源: Karger

ISSN:0030-2414    

DOI:10.1159/000227388

出版商:S. Karger AG    

年代:1994

数据来源: Karger